PEGLOTICASE (K	RYSTEXXA®) PRESCRIBEI	R ORDER FO	RM			
Fax con	npleted form, insurance inform	nation, and clini	cal documentation	to:		
	Patient Name:				Date of Birth:	
option care health	Address:					
	Phone:		Height:	☐ inches ☐	cm Weight:	☐ lbs ☐ kg
Clinical Information						
Primary Diagnosis De	scription: Gout (chronic)	ICD-10 Code:				
Date Methotrexate a	nd Folic Acid Initiated:					
Pogloticaco (Krystovy	a®\ 8 mg/ml 2 ml SDV rofill as		rystexxa®) Prescrip	tion		
Pegloticase (Krystexxa®) 8 mg/mL 2 mL SDV refill as directed x 1 year Infuse 8 mg IV over at least 2 hours every two weeks.						
Pharmacy to contact prescriber for serum uric acid levels greater than 6 mg/dL.						
		Anc	illary Orders			
Anaphylaxis Kit						
 SQ Doses: Epinephrine Auto-Injector 0.3 mg 2-Pack Kit – Inject 0.3 mg IM x 1 dose PRN anaphylactic reaction, repeat x 1 PRN. Diphenhydramine 25 mg (> 30 kg) or 1.25 mg/kg (≤ 30 kg) IV or IM; repeat x 1 in 15 min PRN no improvement. Normal saline 500 mL (> 30 kg) or 250 mL (≤ 30 kg) IV at KVO rate PRN anaphylaxis. Patients ≤ 30 kg, infuse over 2 to 4 hours PRN headache rated > 5 on pain scale. 						
☐ OTC PO ant Take PO the Corticosteroid Pr ☐ Solu-Cortef	ohen 1000 mg PO 30 min before ihistamine of choice and dose: e night prior to infusion and take re-Medications: Select <u>ONE</u> of 200 mg IV prior to infusion. nisolone 80 mg IV prior to infusion.	e dose again 30 the following:	min prior to infusio	on. Patient may d	ecline.	
IV Flush Orders Peripheral: NS 2 to 3 mL pre-/post-use. Implanted Port: NS 5 to 10 mL pre-/post-use and 10 to 20 mL pre-/post-lab draw. Heparin (100 unit/mL) 3 to 5 mL post-use. For maintenance, heparin (100 unit/mL) 3 to 5 mL every 24 hr if accessed or weekly to monthly if not accessed.						
Contact pre AND patien	acid level drawn 1 to 2 days prions of the seriber for serum uric acid levent that not experienced any infuscriber and discontinue Kryster	els greater than sion reactions p	6mg/dL. Recomme	end to dose Kryst		
☐ Other:						
Skilled nurse to admir	nister doses intravenously. Ref	ill above ancillar	y orders as directed	d x 1 year.		
I certify that the use of the indicated treatment is medically necessary and I will be supervising the patient's treatment. Prescriber Signature: Date:						tment.
Prescriber Information						
Prescriber Name:			Phone:		Fax:	
Address:			NPI:			
City, State: Zip:		Zip:	Office Contact:			

CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that don't require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws. IMPORTANT WARNING: This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.